Global Pneumonia Therapeutics Market Size To Grow USD 4.10 Billion by 2030 | CAGR 8.9%

Category: Healthcare

RELEASE DATE Feb 2023
REPORT ID SI1539

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: table

Filename: press/detail.php

Line Number: 118

Backtrace:

File: /home/admin/web/sphericalinsights.com/public_html/application/views/press/detail.php
Line: 118
Function: _error_handler

File: /home/admin/web/sphericalinsights.com/public_html/application/views/layouts/master_header_footer.php
Line: 720
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/application/controllers/Press.php
Line: 89
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/index.php
Line: 295
Function: require_once

Global Pneumonia Therapeutics Market worth $4.10 billion by 2030

According to a research report published by Spherical Insights & Consulting, the Global Pneumonia Therapeutics Market Size to grow from USD 2.60 billion in 2021 to USD 4.10 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 8.9% during the forecast period.

Pneumonia Therapeutics Market

Get more details on this report -

Request Free Sample PDF

 

Browse key industry insights spread across 209 pages with 100 market data tables and figures & charts from the report Global Pneumonia Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Product (Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy), By Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030 in detail along with the table of contents https://www.sphericalinsights.com/reports/pneumonia-therapeutics-market

 

Treatments for pneumonia are used to both treat and ward off the illness. Pneumonia is an infection that harms people's lungs, especially the alveoli. The alveoli become clogged with pus or liquid. A person with pneumonia will experience fever, chills, a cough, and trouble breathing. Influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) are additional common causes of viral pneumonia. Another frequent cause of bacterial pneumonia is streptococcus pneumoniae (pneumococcus). The commercial operations of several enterprises, including preclinical and clinical testing of microbiome-based treatments and diagnostics, have been severely disrupted by COVID-19 and may still be. It is anticipated that the global pneumonia therapeutics market would grow significantly in the coming years due to the rising frequency of infectious diseases and the growing elderly population with impaired immune systems. Also, from 2023 to 2030, the market is expected to grow more quickly due to increasing research and development efforts by a number of industry players in the production of pharmaceuticals and therapeutic agents. An increase in pneumonia cases is predicted to drive the market for pneumonia therapies over the course of the forecast period. Furthermore, a rise in the prevalence of community-acquired pneumonia, particularly in younger people, is expected to fuel market growth in the upcoming years. Also, increased prevalence demonstrates unmet therapeutic needs, which will increase demand for anti-pneumonia medications in the upcoming years. Also, it is projected that a rise in treatment-related R&D will support market expansion. Over the course of the projection period, it is anticipated that a surge in investments in the development of novel products that might be used as treatments for pneumonia would create profitable opportunities for the market's growth. A lack of trained medical personnel who are unable to treat patients with the appropriate medications may impede the growth of the global pneumonia therapeutics market during the forecast period.

 

The Vaccines segment is holding the dominance over the forecast period.

Based on the product, the global pneumonia therapeutics market is segmented into Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy. Among these, the vaccines segment is holding its dominance over the forecast period. The extraordinary demand is due to the high annual cost of pharmaceutical therapy and the insufficient insurance coverage. Due to the rise in resistant strains and the high mortality and morbidity rates associated with pneumococcal infection, prophylactic medication is now in great demand. Profitable development opportunities are predicted as a result of the 5-year immunisation schedule, high preventive rates of these vaccines, and increased regulatory agency support for vaccination. Oxygen treatment is likely to increase at a moderate rate during the estimated time frame. This is related to the rise of randomised controlled studies for assessing the effectiveness of oxygen therapy in intensive care facilities. Also, the great clinical urgency to create techniques for efficient management, which are crucial in minimising effects, drives the demand for oxygen treatment to treat pneumococcal disease.

 

The Prevention Vaccines segment is going to dominate the market over the forecast period.

On the basis of distribution channel, the global pneumonia therapeutics market is segmented into Hospitals, Pharmaceutical Stores, and Others. Among these, the prevention vaccines segment is going to dominate the market over the forecast period. Many outpatients and inpatients are preferring hospitals because they offer pneumonia treatment from skilled professionals. Also, it is anticipated that hospitals would spend more money developing new techniques to treating pneumonia in the general population during the forecast period. The increased adoption of novel and potent treatments for the ailment is another factor contributing to the rise of the pneumonia therapeutics market.

 

Pneumonia Therapeutics Market

Get more details on this report -

Request Free Sample PDF

 

North America is dominating the market over the forecast period.

Among all other regions, North America is dominating the market over the forecast period. This emphasises the need for the development of advanced generation medicines and can be attributed to the ageing population as well as the rise in adult and paediatric multidrug resistance. Players in the global market are focusing on new product development and raising their R&D budgets as a result. Moreover, various government initiatives for the identification, management, and prevention of pneumonia have been successful in North America.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies